Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pulmonary Disease, Chronic Obstructive | 15 | 2014 | 283 | 3.860 |
Why?
|
Hypoglycemic Agents | 15 | 2021 | 211 | 3.800 |
Why?
|
Diabetes Mellitus, Type 2 | 19 | 2018 | 676 | 3.510 |
Why?
|
Cough | 13 | 2021 | 177 | 3.500 |
Why?
|
Thiazolidinediones | 10 | 2015 | 50 | 3.060 |
Why?
|
Cardiovascular Diseases | 15 | 2017 | 803 | 2.640 |
Why?
|
Scopolamine Derivatives | 9 | 2014 | 10 | 2.600 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 6 | 2024 | 147 | 2.440 |
Why?
|
Warfare | 12 | 2014 | 32 | 2.160 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2019 | 219 | 2.150 |
Why?
|
Gastrointestinal Hemorrhage | 5 | 2020 | 82 | 2.080 |
Why?
|
Humans | 181 | 2024 | 57836 | 2.060 |
Why?
|
Cholinergic Antagonists | 6 | 2014 | 25 | 2.020 |
Why?
|
Randomized Controlled Trials as Topic | 25 | 2024 | 643 | 1.990 |
Why?
|
Pancreatitis | 7 | 2015 | 100 | 1.930 |
Why?
|
Drugs, Generic | 3 | 2018 | 17 | 1.810 |
Why?
|
Alzheimer Disease | 3 | 2024 | 496 | 1.650 |
Why?
|
Algorithms | 6 | 2022 | 975 | 1.500 |
Why?
|
Dabigatran | 5 | 2023 | 22 | 1.490 |
Why?
|
Decision Support Techniques | 5 | 2020 | 170 | 1.490 |
Why?
|
Delivery of Health Care | 7 | 2021 | 416 | 1.450 |
Why?
|
Adverse Drug Reaction Reporting Systems | 4 | 2017 | 48 | 1.440 |
Why?
|
Adrenal Cortex Hormones | 5 | 2018 | 136 | 1.340 |
Why?
|
Pneumonia | 6 | 2018 | 260 | 1.310 |
Why?
|
Anticoagulants | 10 | 2023 | 487 | 1.310 |
Why?
|
Research Design | 11 | 2023 | 571 | 1.210 |
Why?
|
Benzazepines | 3 | 2012 | 22 | 1.200 |
Why?
|
Quinoxalines | 3 | 2012 | 34 | 1.170 |
Why?
|
Bronchodilator Agents | 4 | 2014 | 52 | 1.160 |
Why?
|
Myocardial Ischemia | 3 | 2014 | 105 | 1.150 |
Why?
|
Aortic Aneurysm | 2 | 2018 | 83 | 1.140 |
Why?
|
United States Food and Drug Administration | 5 | 2018 | 93 | 1.140 |
Why?
|
Myocardial Infarction | 9 | 2018 | 868 | 1.140 |
Why?
|
Clinical Trials as Topic | 9 | 2018 | 415 | 1.110 |
Why?
|
Administration, Inhalation | 12 | 2014 | 91 | 1.100 |
Why?
|
Evidence-Based Medicine | 8 | 2019 | 449 | 1.070 |
Why?
|
Atrial Fibrillation | 6 | 2023 | 719 | 1.030 |
Why?
|
Warfarin | 6 | 2015 | 109 | 1.010 |
Why?
|
Risk Assessment | 19 | 2020 | 1891 | 0.980 |
Why?
|
Renal Insufficiency | 2 | 2023 | 60 | 0.960 |
Why?
|
Male | 52 | 2024 | 26660 | 0.950 |
Why?
|
Glucagon-Like Peptide 1 | 3 | 2018 | 17 | 0.940 |
Why?
|
Aged | 35 | 2024 | 12844 | 0.920 |
Why?
|
Ipratropium | 3 | 2014 | 7 | 0.910 |
Why?
|
Anti-Bacterial Agents | 4 | 2018 | 660 | 0.900 |
Why?
|
Human Rights | 5 | 2008 | 16 | 0.900 |
Why?
|
Female | 58 | 2024 | 30120 | 0.900 |
Why?
|
Nicotinic Agonists | 3 | 2012 | 40 | 0.890 |
Why?
|
Asthma | 2 | 2022 | 430 | 0.860 |
Why?
|
Primary Prevention | 3 | 2019 | 134 | 0.850 |
Why?
|
Electronic Health Records | 3 | 2022 | 339 | 0.840 |
Why?
|
Periodicals as Topic | 2 | 2020 | 165 | 0.830 |
Why?
|
Anti-Asthmatic Agents | 1 | 2022 | 43 | 0.820 |
Why?
|
Prescription Drugs | 3 | 2018 | 50 | 0.810 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2023 | 107 | 0.800 |
Why?
|
Review Literature as Topic | 5 | 2016 | 37 | 0.780 |
Why?
|
Heart Failure | 7 | 2016 | 828 | 0.780 |
Why?
|
Biological Products | 1 | 2022 | 92 | 0.770 |
Why?
|
Adult | 34 | 2024 | 15396 | 0.760 |
Why?
|
Antiparkinson Agents | 1 | 2021 | 8 | 0.760 |
Why?
|
Dopamine Antagonists | 1 | 2021 | 15 | 0.760 |
Why?
|
Fluoroquinolones | 2 | 2018 | 26 | 0.750 |
Why?
|
HIV Infections | 9 | 2017 | 914 | 0.720 |
Why?
|
Public Health | 3 | 2007 | 179 | 0.710 |
Why?
|
Nepal | 13 | 2016 | 93 | 0.710 |
Why?
|
Tiotropium Bromide | 8 | 2014 | 10 | 0.700 |
Why?
|
Vaccination Coverage | 1 | 2019 | 6 | 0.700 |
Why?
|
Intracranial Hemorrhages | 1 | 2020 | 51 | 0.700 |
Why?
|
Hospitalization | 5 | 2022 | 1252 | 0.690 |
Why?
|
Middle Aged | 36 | 2024 | 15729 | 0.690 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 122 | 0.690 |
Why?
|
Practice Guidelines as Topic | 6 | 2018 | 704 | 0.690 |
Why?
|
Wernicke Encephalopathy | 4 | 2007 | 4 | 0.680 |
Why?
|
Risk Factors | 20 | 2018 | 4930 | 0.670 |
Why?
|
Treatment Outcome | 17 | 2023 | 4912 | 0.670 |
Why?
|
Testosterone | 2 | 2016 | 133 | 0.670 |
Why?
|
Drug Prescriptions | 1 | 2021 | 188 | 0.660 |
Why?
|
Human Rights Abuses | 3 | 2007 | 3 | 0.650 |
Why?
|
Glucocorticoids | 2 | 2011 | 161 | 0.650 |
Why?
|
Cardiovascular System | 1 | 2019 | 38 | 0.650 |
Why?
|
beta-Alanine | 2 | 2015 | 8 | 0.640 |
Why?
|
Myocarditis | 1 | 2019 | 45 | 0.640 |
Why?
|
Death, Sudden, Cardiac | 2 | 2019 | 297 | 0.640 |
Why?
|
Immunologic Factors | 1 | 2019 | 99 | 0.640 |
Why?
|
Refugees | 4 | 2008 | 61 | 0.630 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2015 | 53 | 0.630 |
Why?
|
Patient Participation | 1 | 2020 | 210 | 0.620 |
Why?
|
Thiophenes | 2 | 2015 | 41 | 0.620 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2020 | 209 | 0.620 |
Why?
|
Databases, Factual | 5 | 2021 | 839 | 0.620 |
Why?
|
Cause of Death | 3 | 2019 | 197 | 0.620 |
Why?
|
Morpholines | 2 | 2015 | 84 | 0.620 |
Why?
|
Stroke | 6 | 2023 | 1108 | 0.620 |
Why?
|
Decision Making | 3 | 2018 | 383 | 0.620 |
Why?
|
Statistics as Topic | 1 | 2018 | 151 | 0.610 |
Why?
|
Benzimidazoles | 2 | 2015 | 58 | 0.610 |
Why?
|
United States | 18 | 2023 | 7388 | 0.610 |
Why?
|
Amphetamine | 1 | 2017 | 11 | 0.600 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 253 | 0.600 |
Why?
|
Herpes Zoster | 1 | 2017 | 22 | 0.590 |
Why?
|
Thyroxine | 1 | 2017 | 54 | 0.580 |
Why?
|
Guidelines as Topic | 4 | 2012 | 160 | 0.580 |
Why?
|
Incretins | 1 | 2016 | 5 | 0.570 |
Why?
|
Atherosclerosis | 1 | 2018 | 144 | 0.570 |
Why?
|
Incidence | 9 | 2022 | 1216 | 0.570 |
Why?
|
Cerebrovascular Disorders | 1 | 2017 | 70 | 0.570 |
Why?
|
Antithrombins | 1 | 2017 | 15 | 0.560 |
Why?
|
Disasters | 2 | 2014 | 28 | 0.550 |
Why?
|
Lung Neoplasms | 2 | 2020 | 532 | 0.540 |
Why?
|
Bronchitis | 2 | 2020 | 23 | 0.530 |
Why?
|
Health Services Accessibility | 6 | 2009 | 532 | 0.530 |
Why?
|
Pharyngitis | 2 | 2006 | 12 | 0.520 |
Why?
|
Streptococcus pyogenes | 2 | 2006 | 27 | 0.520 |
Why?
|
Arrhythmias, Cardiac | 2 | 2016 | 134 | 0.520 |
Why?
|
Rhabdomyolysis | 2 | 2006 | 26 | 0.510 |
Why?
|
Fluorobenzenes | 2 | 2005 | 5 | 0.510 |
Why?
|
Streptococcal Infections | 2 | 2006 | 77 | 0.510 |
Why?
|
Pharmacoepidemiology | 1 | 2014 | 12 | 0.500 |
Why?
|
Vena Cava Filters | 2 | 2014 | 21 | 0.490 |
Why?
|
Fractures, Bone | 3 | 2011 | 149 | 0.490 |
Why?
|
Risk | 7 | 2020 | 374 | 0.490 |
Why?
|
Heptanoic Acids | 2 | 2004 | 20 | 0.490 |
Why?
|
Pyrroles | 2 | 2004 | 48 | 0.480 |
Why?
|
Pyrimidines | 2 | 2005 | 116 | 0.480 |
Why?
|
Sulfonamides | 2 | 2005 | 124 | 0.470 |
Why?
|
Embolism, Paradoxical | 1 | 2014 | 12 | 0.460 |
Why?
|
Developing Countries | 4 | 2008 | 80 | 0.460 |
Why?
|
Aged, 80 and over | 12 | 2021 | 4913 | 0.460 |
Why?
|
Medication Adherence | 2 | 2015 | 262 | 0.460 |
Why?
|
Bariatric Surgery | 3 | 2013 | 43 | 0.460 |
Why?
|
Urinary Retention | 2 | 2011 | 29 | 0.450 |
Why?
|
Azasteroids | 1 | 2013 | 2 | 0.450 |
Why?
|
5-alpha Reductase Inhibitors | 1 | 2013 | 6 | 0.450 |
Why?
|
Health Planning Guidelines | 1 | 2013 | 33 | 0.450 |
Why?
|
Valproic Acid | 1 | 2013 | 24 | 0.450 |
Why?
|
Age Factors | 8 | 2021 | 1537 | 0.440 |
Why?
|
Consensus | 3 | 2018 | 178 | 0.440 |
Why?
|
Relief Work | 3 | 2007 | 13 | 0.440 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 1340 | 0.440 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2014 | 802 | 0.440 |
Why?
|
Biomedical Research | 3 | 2013 | 241 | 0.430 |
Why?
|
Meta-Analysis as Topic | 5 | 2015 | 76 | 0.430 |
Why?
|
Child Development Disorders, Pervasive | 1 | 2013 | 52 | 0.430 |
Why?
|
Anticonvulsants | 1 | 2013 | 92 | 0.430 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 319 | 0.430 |
Why?
|
Insulin | 1 | 2016 | 696 | 0.420 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2012 | 8 | 0.420 |
Why?
|
Epilepsy | 1 | 2013 | 99 | 0.410 |
Why?
|
Tobacco Use Cessation | 1 | 2012 | 30 | 0.410 |
Why?
|
Polypharmacy | 2 | 2024 | 63 | 0.410 |
Why?
|
Macular Edema | 1 | 2012 | 24 | 0.410 |
Why?
|
Pancreatic Neoplasms | 1 | 2015 | 319 | 0.410 |
Why?
|
Cohort Studies | 5 | 2021 | 2381 | 0.400 |
Why?
|
Bupropion | 1 | 2011 | 8 | 0.400 |
Why?
|
Chronic Disease | 6 | 2021 | 735 | 0.400 |
Why?
|
Acute Disease | 6 | 2020 | 671 | 0.400 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2013 | 164 | 0.400 |
Why?
|
Diabetic Angiopathies | 2 | 2008 | 24 | 0.390 |
Why?
|
Mucociliary Clearance | 1 | 2021 | 5 | 0.390 |
Why?
|
Reflex | 1 | 2021 | 28 | 0.380 |
Why?
|
Venoms | 3 | 2016 | 11 | 0.380 |
Why?
|
Administration, Oral | 5 | 2023 | 342 | 0.380 |
Why?
|
Wounds and Injuries | 1 | 2014 | 241 | 0.380 |
Why?
|
Opportunistic Infections | 1 | 2011 | 27 | 0.380 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 4 | 2021 | 10 | 0.380 |
Why?
|
Autistic Disorder | 1 | 2013 | 164 | 0.370 |
Why?
|
Nicotine | 1 | 2011 | 110 | 0.370 |
Why?
|
Product Surveillance, Postmarketing | 4 | 2012 | 22 | 0.360 |
Why?
|
Respiratory Tract Infections | 1 | 2011 | 77 | 0.360 |
Why?
|
Bronchitis, Chronic | 1 | 2020 | 4 | 0.360 |
Why?
|
Reproducibility of Results | 4 | 2022 | 1514 | 0.360 |
Why?
|
Lower Extremity | 3 | 2021 | 143 | 0.350 |
Why?
|
Eosinophilia | 1 | 2020 | 25 | 0.350 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 199 | 0.350 |
Why?
|
Quality of Life | 3 | 2020 | 1023 | 0.350 |
Why?
|
Retrospective Studies | 10 | 2023 | 5749 | 0.350 |
Why?
|
Suicide | 1 | 2011 | 121 | 0.350 |
Why?
|
Child | 11 | 2020 | 4312 | 0.340 |
Why?
|
Outpatients | 2 | 2020 | 131 | 0.340 |
Why?
|
International Cooperation | 5 | 2008 | 84 | 0.340 |
Why?
|
Glucagon-Like Peptide-1 Receptor | 2 | 2021 | 15 | 0.340 |
Why?
|
Mortality | 3 | 2018 | 154 | 0.340 |
Why?
|
Postoperative Complications | 4 | 2013 | 1079 | 0.330 |
Why?
|
Kidney Failure, Chronic | 2 | 2008 | 187 | 0.330 |
Why?
|
Observational Studies as Topic | 3 | 2019 | 54 | 0.330 |
Why?
|
Diphosphonates | 1 | 2009 | 35 | 0.330 |
Why?
|
Outsourced Services | 1 | 2008 | 3 | 0.330 |
Why?
|
Health | 2 | 2006 | 33 | 0.330 |
Why?
|
Polyethylene Glycols | 2 | 2023 | 163 | 0.320 |
Why?
|
Whooping Cough | 1 | 2018 | 15 | 0.320 |
Why?
|
Gastroesophageal Reflux | 1 | 2019 | 72 | 0.320 |
Why?
|
Depression | 3 | 2014 | 872 | 0.320 |
Why?
|
Bone Density Conservation Agents | 1 | 2009 | 51 | 0.320 |
Why?
|
Publication Bias | 4 | 2012 | 21 | 0.320 |
Why?
|
Emigration and Immigration | 2 | 2008 | 25 | 0.320 |
Why?
|
Pregnancy Complications | 1 | 2013 | 398 | 0.320 |
Why?
|
Bronchiolitis, Viral | 1 | 2018 | 4 | 0.320 |
Why?
|
Patient Education as Topic | 2 | 2011 | 454 | 0.310 |
Why?
|
Disaster Planning | 3 | 2015 | 50 | 0.310 |
Why?
|
Stomatitis | 1 | 2008 | 6 | 0.310 |
Why?
|
Simvastatin | 2 | 2005 | 29 | 0.310 |
Why?
|
Lung Diseases, Interstitial | 1 | 2018 | 48 | 0.310 |
Why?
|
Attitude to Health | 2 | 2008 | 285 | 0.300 |
Why?
|
Antiviral Agents | 2 | 2023 | 317 | 0.300 |
Why?
|
Adolescent | 9 | 2020 | 5912 | 0.300 |
Why?
|
Hemorrhage | 3 | 2023 | 275 | 0.300 |
Why?
|
Secondary Prevention | 2 | 2019 | 149 | 0.300 |
Why?
|
Interferon-alpha | 1 | 2008 | 99 | 0.300 |
Why?
|
Patient Advocacy | 1 | 2007 | 29 | 0.290 |
Why?
|
Civil Disorders | 1 | 2007 | 2 | 0.290 |
Why?
|
Peptides | 3 | 2016 | 546 | 0.290 |
Why?
|
Lisinopril | 1 | 2006 | 4 | 0.290 |
Why?
|
Child Welfare | 2 | 2009 | 55 | 0.280 |
Why?
|
Young Adult | 7 | 2021 | 4205 | 0.280 |
Why?
|
Contrast Media | 2 | 2008 | 388 | 0.280 |
Why?
|
Critical Illness | 1 | 2020 | 324 | 0.280 |
Why?
|
Mass Screening | 2 | 2017 | 629 | 0.280 |
Why?
|
Renal Dialysis | 1 | 2008 | 187 | 0.280 |
Why?
|
Sample Size | 4 | 2023 | 59 | 0.270 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2017 | 104 | 0.270 |
Why?
|
Information Dissemination | 1 | 2007 | 112 | 0.270 |
Why?
|
Amiodarone | 1 | 2006 | 18 | 0.270 |
Why?
|
Pulmonary Alveoli | 1 | 2006 | 41 | 0.270 |
Why?
|
Influenza, Human | 1 | 2018 | 186 | 0.270 |
Why?
|
Hydralazine | 1 | 2006 | 1 | 0.270 |
Why?
|
Clinical Clerkship | 1 | 2006 | 83 | 0.270 |
Why?
|
Smoking Cessation | 1 | 2011 | 544 | 0.270 |
Why?
|
Self Care | 1 | 2008 | 209 | 0.270 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2006 | 142 | 0.270 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2006 | 65 | 0.260 |
Why?
|
Vasodilator Agents | 1 | 2006 | 57 | 0.260 |
Why?
|
Internal Medicine | 1 | 2006 | 146 | 0.260 |
Why?
|
Vasoconstrictor Agents | 1 | 2006 | 61 | 0.260 |
Why?
|
Myelography | 1 | 2005 | 1 | 0.260 |
Why?
|
Religion and Medicine | 1 | 2005 | 23 | 0.260 |
Why?
|
Iopamidol | 1 | 2005 | 16 | 0.260 |
Why?
|
Cocaine-Related Disorders | 1 | 2006 | 74 | 0.250 |
Why?
|
Patient Selection | 5 | 2015 | 424 | 0.250 |
Why?
|
Aging | 1 | 2021 | 720 | 0.250 |
Why?
|
Bariatrics | 1 | 2005 | 1 | 0.250 |
Why?
|
Religion | 1 | 2005 | 34 | 0.250 |
Why?
|
Aminopyridines | 2 | 2016 | 21 | 0.250 |
Why?
|
Carotid Stenosis | 1 | 2006 | 99 | 0.250 |
Why?
|
Pharynx | 1 | 2005 | 20 | 0.250 |
Why?
|
Cocaine | 1 | 2006 | 85 | 0.250 |
Why?
|
Benzamides | 2 | 2016 | 49 | 0.250 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2005 | 27 | 0.250 |
Why?
|
Disease Outbreaks | 1 | 2005 | 103 | 0.250 |
Why?
|
Formularies as Topic | 1 | 2004 | 2 | 0.250 |
Why?
|
Patient-Centered Care | 2 | 2019 | 242 | 0.250 |
Why?
|
Community Health Services | 1 | 2006 | 134 | 0.250 |
Why?
|
Lung Diseases | 1 | 2006 | 145 | 0.240 |
Why?
|
Referral and Consultation | 1 | 2008 | 399 | 0.240 |
Why?
|
Social Justice | 1 | 2004 | 31 | 0.240 |
Why?
|
Follow-Up Studies | 4 | 2018 | 2238 | 0.240 |
Why?
|
Seizures | 1 | 2005 | 111 | 0.240 |
Why?
|
Societies, Medical | 1 | 2006 | 306 | 0.240 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2006 | 156 | 0.240 |
Why?
|
Kidney Transplantation | 1 | 2006 | 254 | 0.240 |
Why?
|
Healthcare Disparities | 1 | 2008 | 330 | 0.230 |
Why?
|
Antipsychotic Agents | 2 | 2015 | 311 | 0.230 |
Why?
|
Acute Kidney Injury | 1 | 2006 | 126 | 0.230 |
Why?
|
Potentially Inappropriate Medication List | 1 | 2024 | 14 | 0.230 |
Why?
|
Bias | 3 | 2014 | 110 | 0.230 |
Why?
|
Drug Therapy, Combination | 5 | 2018 | 418 | 0.230 |
Why?
|
Drug Administration Schedule | 3 | 2014 | 279 | 0.230 |
Why?
|
Health Services | 1 | 2004 | 87 | 0.230 |
Why?
|
Vaccination | 5 | 2024 | 323 | 0.230 |
Why?
|
Tenofovir | 1 | 2023 | 8 | 0.220 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2009 | 736 | 0.220 |
Why?
|
Obesity | 2 | 2013 | 1221 | 0.220 |
Why?
|
Inappropriate Prescribing | 1 | 2024 | 63 | 0.220 |
Why?
|
Socioeconomic Factors | 5 | 2016 | 794 | 0.220 |
Why?
|
Qualitative Research | 3 | 2024 | 570 | 0.220 |
Why?
|
Adenine | 1 | 2023 | 43 | 0.220 |
Why?
|
Heart Transplantation | 1 | 2004 | 144 | 0.220 |
Why?
|
Child Abuse | 1 | 2004 | 88 | 0.220 |
Why?
|
Rivaroxaban | 3 | 2023 | 19 | 0.220 |
Why?
|
Physicians | 3 | 2022 | 440 | 0.220 |
Why?
|
Military Personnel | 1 | 2004 | 97 | 0.220 |
Why?
|
Blood Glucose | 3 | 2018 | 482 | 0.220 |
Why?
|
Focus Groups | 1 | 2024 | 291 | 0.210 |
Why?
|
Health Expenditures | 1 | 2004 | 110 | 0.210 |
Why?
|
Acquired Immunodeficiency Syndrome | 3 | 2009 | 138 | 0.210 |
Why?
|
Intracranial Aneurysm | 1 | 2006 | 293 | 0.210 |
Why?
|
Ivermectin | 1 | 2022 | 10 | 0.210 |
Why?
|
Dementia | 1 | 2005 | 232 | 0.210 |
Why?
|
Influenza Vaccines | 1 | 2023 | 85 | 0.200 |
Why?
|
Kidney | 2 | 2023 | 387 | 0.200 |
Why?
|
Varenicline | 2 | 2011 | 12 | 0.200 |
Why?
|
Caregivers | 1 | 2024 | 211 | 0.200 |
Why?
|
Hypertension | 1 | 2007 | 603 | 0.200 |
Why?
|
International Classification of Diseases | 2 | 2019 | 143 | 0.190 |
Why?
|
Venous Thromboembolism | 2 | 2013 | 155 | 0.190 |
Why?
|
Medication Systems | 1 | 2021 | 18 | 0.190 |
Why?
|
Double-Blind Method | 3 | 2023 | 641 | 0.190 |
Why?
|
Communication | 3 | 2024 | 523 | 0.190 |
Why?
|
Pilot Projects | 3 | 2017 | 893 | 0.190 |
Why?
|
Delphi Technique | 3 | 2019 | 76 | 0.190 |
Why?
|
Diuretics | 1 | 2021 | 58 | 0.190 |
Why?
|
Calcium Channel Blockers | 1 | 2021 | 53 | 0.190 |
Why?
|
Pharmacy | 1 | 2021 | 18 | 0.190 |
Why?
|
Data Collection | 2 | 2019 | 392 | 0.190 |
Why?
|
Ambulatory Care | 3 | 2023 | 285 | 0.180 |
Why?
|
Proton Pump Inhibitors | 2 | 2019 | 36 | 0.180 |
Why?
|
Case-Control Studies | 3 | 2013 | 1030 | 0.180 |
Why?
|
Medication Errors | 1 | 2021 | 114 | 0.180 |
Why?
|
Anti-Infective Agents | 1 | 2022 | 133 | 0.180 |
Why?
|
Severity of Illness Index | 2 | 2020 | 1385 | 0.180 |
Why?
|
Safety Management | 2 | 2012 | 144 | 0.180 |
Why?
|
Vaccines | 1 | 2021 | 96 | 0.180 |
Why?
|
Drug Labeling | 2 | 2012 | 28 | 0.180 |
Why?
|
Primary Health Care | 2 | 2024 | 630 | 0.180 |
Why?
|
Peripheral Arterial Disease | 2 | 2020 | 147 | 0.180 |
Why?
|
Prevalence | 5 | 2013 | 1269 | 0.170 |
Why?
|
Pharmacists | 1 | 2021 | 123 | 0.170 |
Why?
|
Death Certificates | 1 | 2019 | 9 | 0.170 |
Why?
|
Prognosis | 3 | 2014 | 1505 | 0.170 |
Why?
|
Patient Safety | 2 | 2012 | 234 | 0.170 |
Why?
|
Vulnerable Populations | 2 | 2013 | 82 | 0.170 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 33 | 0.170 |
Why?
|
Medicare | 1 | 2023 | 583 | 0.160 |
Why?
|
Reminder Systems | 1 | 2019 | 72 | 0.160 |
Why?
|
Canagliflozin | 1 | 2018 | 4 | 0.160 |
Why?
|
Armed Conflicts | 1 | 2018 | 3 | 0.160 |
Why?
|
Health Status | 2 | 2016 | 441 | 0.160 |
Why?
|
Exposure to Violence | 1 | 2018 | 5 | 0.160 |
Why?
|
Data Interpretation, Statistical | 3 | 2015 | 198 | 0.160 |
Why?
|
Health Facilities | 1 | 2018 | 42 | 0.150 |
Why?
|
Comparative Effectiveness Research | 3 | 2013 | 44 | 0.150 |
Why?
|
Quality Control | 1 | 2018 | 69 | 0.150 |
Why?
|
Education | 1 | 2018 | 75 | 0.150 |
Why?
|
Health Education | 1 | 2019 | 187 | 0.150 |
Why?
|
Osteoporotic Fractures | 1 | 2018 | 35 | 0.150 |
Why?
|
Multiple Chronic Conditions | 1 | 2018 | 36 | 0.150 |
Why?
|
Budesonide | 2 | 2023 | 11 | 0.150 |
Why?
|
Cooperative Behavior | 1 | 2019 | 218 | 0.150 |
Why?
|
Respiratory Function Tests | 2 | 2009 | 114 | 0.150 |
Why?
|
Herpes Zoster Ophthalmicus | 1 | 2017 | 6 | 0.150 |
Why?
|
Torture | 2 | 2008 | 2 | 0.150 |
Why?
|
Metformin | 2 | 2015 | 69 | 0.150 |
Why?
|
Crime Victims | 1 | 2018 | 50 | 0.150 |
Why?
|
Population Surveillance | 1 | 2018 | 210 | 0.150 |
Why?
|
Practice Patterns, Physicians' | 2 | 2021 | 733 | 0.140 |
Why?
|
Insulin Detemir | 1 | 2016 | 1 | 0.140 |
Why?
|
Glucagon-Like Peptides | 1 | 2016 | 1 | 0.140 |
Why?
|
Insulin Glargine | 1 | 2016 | 2 | 0.140 |
Why?
|
Insulin, Long-Acting | 1 | 2016 | 2 | 0.140 |
Why?
|
Liraglutide | 1 | 2016 | 4 | 0.140 |
Why?
|
Observer Variation | 1 | 2017 | 193 | 0.140 |
Why?
|
Medical Records | 1 | 2017 | 134 | 0.140 |
Why?
|
Stress, Psychological | 2 | 2014 | 440 | 0.140 |
Why?
|
Cross-Sectional Studies | 3 | 2019 | 2416 | 0.140 |
Why?
|
Hormone Replacement Therapy | 1 | 2016 | 37 | 0.140 |
Why?
|
Thiamine Deficiency | 2 | 2007 | 5 | 0.140 |
Why?
|
Androgens | 1 | 2016 | 56 | 0.140 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2016 | 48 | 0.140 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2006 | 98 | 0.140 |
Why?
|
China | 2 | 2008 | 136 | 0.140 |
Why?
|
Drug Evaluation | 1 | 2016 | 20 | 0.140 |
Why?
|
Widowhood | 1 | 2016 | 4 | 0.140 |
Why?
|
Surge Capacity | 1 | 2015 | 1 | 0.130 |
Why?
|
Social Isolation | 1 | 2016 | 29 | 0.130 |
Why?
|
Hypoglycemia | 1 | 2016 | 68 | 0.130 |
Why?
|
Drug Interactions | 2 | 2007 | 112 | 0.130 |
Why?
|
Research | 2 | 2015 | 193 | 0.130 |
Why?
|
Registries | 1 | 2019 | 805 | 0.130 |
Why?
|
Sensitivity and Specificity | 3 | 2014 | 1054 | 0.130 |
Why?
|
Insurance Claim Review | 1 | 2015 | 81 | 0.130 |
Why?
|
Rosuvastatin Calcium | 2 | 2005 | 3 | 0.130 |
Why?
|
Checklist | 1 | 2016 | 74 | 0.130 |
Why?
|
Hospital Mortality | 1 | 2020 | 872 | 0.130 |
Why?
|
Altruism | 1 | 2014 | 13 | 0.120 |
Why?
|
Adrenomedullin | 1 | 2014 | 1 | 0.120 |
Why?
|
Comorbidity | 1 | 2018 | 1091 | 0.120 |
Why?
|
Recombinant Fusion Proteins | 1 | 2016 | 501 | 0.120 |
Why?
|
Publishing | 1 | 2016 | 87 | 0.120 |
Why?
|
Cognitive Dysfunction | 1 | 2018 | 250 | 0.120 |
Why?
|
Multiple Myeloma | 1 | 2019 | 312 | 0.120 |
Why?
|
Protein Precursors | 1 | 2014 | 71 | 0.120 |
Why?
|
Violence | 2 | 2007 | 185 | 0.120 |
Why?
|
Health Services Needs and Demand | 2 | 2007 | 210 | 0.120 |
Why?
|
Aspirin | 1 | 2015 | 189 | 0.120 |
Why?
|
Phosphodiesterase 4 Inhibitors | 1 | 2013 | 2 | 0.120 |
Why?
|
Health Services Research | 1 | 2015 | 274 | 0.120 |
Why?
|
Bibliometrics | 1 | 2013 | 26 | 0.120 |
Why?
|
Patient Compliance | 2 | 2006 | 379 | 0.110 |
Why?
|
Dutasteride | 1 | 2013 | 1 | 0.110 |
Why?
|
Prostatic Diseases | 1 | 2013 | 5 | 0.110 |
Why?
|
Pakistan | 1 | 2013 | 14 | 0.110 |
Why?
|
Publications | 1 | 2013 | 27 | 0.110 |
Why?
|
Sitagliptin Phosphate | 1 | 2013 | 2 | 0.110 |
Why?
|
Time Factors | 3 | 2011 | 3508 | 0.110 |
Why?
|
Sex Workers | 1 | 2013 | 16 | 0.110 |
Why?
|
Meditation | 1 | 2014 | 59 | 0.110 |
Why?
|
Diabetes Mellitus | 1 | 2018 | 541 | 0.110 |
Why?
|
Bone Density | 2 | 2018 | 178 | 0.110 |
Why?
|
Emergency Medicine | 1 | 2015 | 180 | 0.110 |
Why?
|
Tetrabenazine | 1 | 2013 | 1 | 0.110 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2013 | 14 | 0.110 |
Why?
|
Pyrazines | 1 | 2013 | 32 | 0.110 |
Why?
|
Drug Recalls | 1 | 2012 | 1 | 0.110 |
Why?
|
Affect | 1 | 2014 | 124 | 0.110 |
Why?
|
Triazoles | 1 | 2013 | 55 | 0.110 |
Why?
|
Social Support | 1 | 2016 | 366 | 0.110 |
Why?
|
Prospective Studies | 2 | 2017 | 2999 | 0.110 |
Why?
|
Substance Abuse, Intravenous | 1 | 2013 | 73 | 0.110 |
Why?
|
Therapeutic Equivalency | 1 | 2012 | 9 | 0.110 |
Why?
|
Endpoint Determination | 1 | 2012 | 21 | 0.110 |
Why?
|
Risk Reduction Behavior | 1 | 2013 | 129 | 0.100 |
Why?
|
Histamine H2 Antagonists | 1 | 2012 | 10 | 0.100 |
Why?
|
Neoplasms | 2 | 2015 | 1179 | 0.100 |
Why?
|
Bayes Theorem | 2 | 2023 | 106 | 0.100 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2012 | 32 | 0.100 |
Why?
|
MP3-Player | 1 | 2011 | 2 | 0.100 |
Why?
|
Suicidal Ideation | 1 | 2013 | 113 | 0.100 |
Why?
|
Androstadienes | 1 | 2011 | 13 | 0.100 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 986 | 0.100 |
Why?
|
Fluticasone | 1 | 2011 | 6 | 0.100 |
Why?
|
Huntington Disease | 1 | 2013 | 146 | 0.100 |
Why?
|
Neuromuscular Diseases | 1 | 2021 | 20 | 0.100 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2013 | 238 | 0.100 |
Why?
|
Health Care Rationing | 2 | 2015 | 20 | 0.090 |
Why?
|
Survival Analysis | 1 | 2012 | 553 | 0.090 |
Why?
|
Salmeterol Xinafoate | 1 | 2010 | 3 | 0.090 |
Why?
|
Observation | 1 | 2010 | 26 | 0.090 |
Why?
|
Albuterol | 1 | 2010 | 17 | 0.090 |
Why?
|
Reference Values | 1 | 2011 | 329 | 0.090 |
Why?
|
Mental Disorders | 2 | 2009 | 792 | 0.090 |
Why?
|
Patient Satisfaction | 2 | 2011 | 415 | 0.090 |
Why?
|
Symptom Flare Up | 1 | 2020 | 11 | 0.090 |
Why?
|
Biomechanical Phenomena | 1 | 2021 | 257 | 0.090 |
Why?
|
Symptom Assessment | 1 | 2020 | 41 | 0.090 |
Why?
|
Needs Assessment | 2 | 2015 | 178 | 0.090 |
Why?
|
Technology, Pharmaceutical | 1 | 2009 | 19 | 0.090 |
Why?
|
Quality Indicators, Health Care | 1 | 2012 | 334 | 0.080 |
Why?
|
Respiratory Aspiration | 1 | 2009 | 5 | 0.080 |
Why?
|
Logistic Models | 1 | 2013 | 1267 | 0.080 |
Why?
|
Program Evaluation | 2 | 2011 | 480 | 0.080 |
Why?
|
Anti-Retroviral Agents | 1 | 2009 | 75 | 0.080 |
Why?
|
Sodium Bicarbonate | 1 | 2008 | 11 | 0.080 |
Why?
|
Bronchoscopy | 1 | 2009 | 56 | 0.080 |
Why?
|
Latin America | 1 | 2008 | 14 | 0.080 |
Why?
|
Africa | 1 | 2008 | 20 | 0.080 |
Why?
|
Drug Discovery | 1 | 2009 | 83 | 0.080 |
Why?
|
Foreign Bodies | 1 | 2009 | 42 | 0.080 |
Why?
|
Japan | 1 | 2008 | 58 | 0.080 |
Why?
|
Russia | 1 | 2008 | 53 | 0.080 |
Why?
|
Taiwan | 2 | 2021 | 6 | 0.080 |
Why?
|
Sarcoidosis, Pulmonary | 1 | 2018 | 9 | 0.080 |
Why?
|
Scleroderma, Systemic | 1 | 2018 | 13 | 0.080 |
Why?
|
Thiamine | 2 | 2007 | 19 | 0.080 |
Why?
|
Tibet | 2 | 2006 | 2 | 0.080 |
Why?
|
Government Regulation | 1 | 2008 | 44 | 0.080 |
Why?
|
Colorectal Neoplasms | 1 | 2011 | 255 | 0.080 |
Why?
|
Research Support as Topic | 1 | 2008 | 44 | 0.080 |
Why?
|
Drug Industry | 1 | 2008 | 42 | 0.080 |
Why?
|
Odds Ratio | 2 | 2008 | 805 | 0.080 |
Why?
|
Sex Factors | 1 | 2021 | 951 | 0.080 |
Why?
|
Kidney Function Tests | 1 | 2008 | 34 | 0.080 |
Why?
|
India | 1 | 2008 | 154 | 0.080 |
Why?
|
Nephrology | 1 | 2008 | 15 | 0.080 |
Why?
|
Sulfonylurea Compounds | 2 | 2020 | 14 | 0.080 |
Why?
|
Recurrence | 2 | 2012 | 552 | 0.080 |
Why?
|
Anti-HIV Agents | 2 | 2006 | 152 | 0.080 |
Why?
|
Health Personnel | 2 | 2018 | 357 | 0.080 |
Why?
|
Causality | 1 | 2008 | 56 | 0.080 |
Why?
|
Cardiac Output, Low | 1 | 2007 | 10 | 0.080 |
Why?
|
Postgastrectomy Syndromes | 1 | 2007 | 4 | 0.080 |
Why?
|
Rwanda | 1 | 2007 | 13 | 0.080 |
Why?
|
Malabsorption Syndromes | 1 | 2007 | 4 | 0.080 |
Why?
|
Anecdotes as Topic | 1 | 2007 | 10 | 0.080 |
Why?
|
Toxins, Biological | 1 | 2007 | 6 | 0.070 |
Why?
|
New York City | 1 | 2007 | 73 | 0.070 |
Why?
|
Patient Care Planning | 1 | 2008 | 84 | 0.070 |
Why?
|
Catheters, Indwelling | 1 | 2008 | 62 | 0.070 |
Why?
|
Osteoporosis | 1 | 2009 | 145 | 0.070 |
Why?
|
Homicide | 1 | 2007 | 27 | 0.070 |
Why?
|
Internet | 1 | 2011 | 458 | 0.070 |
Why?
|
Homosexuality, Male | 1 | 2007 | 35 | 0.070 |
Why?
|
Public Policy | 1 | 2008 | 43 | 0.070 |
Why?
|
Health Policy | 2 | 2008 | 180 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2008 | 152 | 0.070 |
Why?
|
Child, Preschool | 2 | 2020 | 1852 | 0.070 |
Why?
|
Communicable Disease Control | 1 | 2007 | 37 | 0.070 |
Why?
|
Anxiety | 2 | 2014 | 397 | 0.070 |
Why?
|
Catheterization, Central Venous | 1 | 2008 | 86 | 0.070 |
Why?
|
Theft | 1 | 2006 | 3 | 0.070 |
Why?
|
Developed Countries | 1 | 2006 | 14 | 0.070 |
Why?
|
Disease Susceptibility | 1 | 2007 | 156 | 0.070 |
Why?
|
Communicable Diseases | 1 | 2007 | 76 | 0.070 |
Why?
|
Safety | 1 | 2007 | 142 | 0.070 |
Why?
|
Educational Status | 1 | 2008 | 273 | 0.070 |
Why?
|
Minority Groups | 1 | 2008 | 132 | 0.070 |
Why?
|
History, 21st Century | 1 | 2007 | 162 | 0.070 |
Why?
|
Vascular Neoplasms | 1 | 2006 | 15 | 0.070 |
Why?
|
HIV | 1 | 2006 | 69 | 0.070 |
Why?
|
Infant Mortality | 1 | 2006 | 20 | 0.070 |
Why?
|
Biomarkers | 2 | 2014 | 1133 | 0.070 |
Why?
|
Police | 1 | 2006 | 37 | 0.070 |
Why?
|
Expert Systems | 1 | 2006 | 6 | 0.070 |
Why?
|
Life Change Events | 1 | 2006 | 66 | 0.070 |
Why?
|
History, 20th Century | 1 | 2007 | 236 | 0.070 |
Why?
|
Penicillins | 1 | 2006 | 27 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2008 | 305 | 0.070 |
Why?
|
Ethics, Research | 1 | 2006 | 19 | 0.070 |
Why?
|
Likelihood Functions | 1 | 2006 | 74 | 0.070 |
Why?
|
Vasoconstriction | 1 | 2006 | 18 | 0.070 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2006 | 61 | 0.070 |
Why?
|
Pregnancy | 1 | 2013 | 2352 | 0.070 |
Why?
|
Endarterectomy, Carotid | 1 | 2006 | 85 | 0.060 |
Why?
|
Recombinant Proteins | 1 | 2008 | 687 | 0.060 |
Why?
|
AIDS Vaccines | 1 | 2006 | 64 | 0.060 |
Why?
|
Maternal Health Services | 1 | 2006 | 64 | 0.060 |
Why?
|
Child Health Services | 1 | 2006 | 65 | 0.060 |
Why?
|
Condoms | 1 | 2005 | 47 | 0.060 |
Why?
|
Thrombosis | 1 | 2008 | 193 | 0.060 |
Why?
|
Decision Support Systems, Clinical | 1 | 2006 | 68 | 0.060 |
Why?
|
Diabetic Nephropathies | 1 | 2005 | 36 | 0.060 |
Why?
|
Patient Care Team | 1 | 2008 | 305 | 0.060 |
Why?
|
Horner Syndrome | 1 | 2005 | 1 | 0.060 |
Why?
|
Communism | 1 | 2004 | 1 | 0.060 |
Why?
|
War Crimes | 1 | 2004 | 2 | 0.060 |
Why?
|
Carotid Artery, Internal, Dissection | 1 | 2005 | 11 | 0.060 |
Why?
|
Nutrition Disorders | 1 | 2004 | 6 | 0.060 |
Why?
|
Educational Measurement | 1 | 2006 | 202 | 0.060 |
Why?
|
Principle-Based Ethics | 1 | 2004 | 2 | 0.060 |
Why?
|
Cyclopropanes | 2 | 2016 | 39 | 0.060 |
Why?
|
Psychology, Child | 1 | 2004 | 6 | 0.060 |
Why?
|
Resource Allocation | 1 | 2004 | 18 | 0.060 |
Why?
|
Poverty | 1 | 2007 | 295 | 0.060 |
Why?
|
Family Practice | 1 | 2006 | 202 | 0.060 |
Why?
|
Infant | 2 | 2006 | 1522 | 0.060 |
Why?
|
Rural Health | 1 | 2004 | 15 | 0.060 |
Why?
|
Health Planning | 1 | 2004 | 27 | 0.060 |
Why?
|
Malaria, Vivax | 1 | 2005 | 33 | 0.060 |
Why?
|
Education, Medical | 1 | 2006 | 172 | 0.060 |
Why?
|
Cyclosporine | 1 | 2004 | 55 | 0.060 |
Why?
|
Total Quality Management | 1 | 2004 | 57 | 0.060 |
Why?
|
Tachycardia, Ventricular | 1 | 2006 | 95 | 0.060 |
Why?
|
Child Advocacy | 1 | 2004 | 7 | 0.060 |
Why?
|
Drug Utilization | 1 | 2006 | 229 | 0.060 |
Why?
|
Drug Delivery Systems | 1 | 2008 | 299 | 0.060 |
Why?
|
Morbidity | 1 | 2004 | 103 | 0.060 |
Why?
|
Massachusetts | 2 | 2021 | 2134 | 0.060 |
Why?
|
Postoperative Care | 1 | 2004 | 104 | 0.060 |
Why?
|
Gastric Bypass | 1 | 2004 | 73 | 0.060 |
Why?
|
Medicaid | 2 | 2019 | 340 | 0.060 |
Why?
|
Africa South of the Sahara | 3 | 2009 | 16 | 0.060 |
Why?
|
Trust | 1 | 2024 | 65 | 0.060 |
Why?
|
Pyridones | 1 | 2023 | 28 | 0.060 |
Why?
|
Pragmatic Clinical Trials as Topic | 1 | 2023 | 4 | 0.060 |
Why?
|
Factor Xa Inhibitors | 1 | 2023 | 35 | 0.060 |
Why?
|
Physicians, Primary Care | 1 | 2024 | 73 | 0.060 |
Why?
|
Fluvoxamine | 1 | 2023 | 1 | 0.060 |
Why?
|
Students, Medical | 1 | 2006 | 238 | 0.060 |
Why?
|
Embolization, Therapeutic | 1 | 2006 | 267 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2006 | 859 | 0.050 |
Why?
|
Injections, Subcutaneous | 1 | 2023 | 71 | 0.050 |
Why?
|
Stents | 1 | 2006 | 399 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2004 | 279 | 0.050 |
Why?
|
Curriculum | 1 | 2006 | 534 | 0.050 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2023 | 97 | 0.050 |
Why?
|
United States Agency for Healthcare Research and Quality | 2 | 2012 | 30 | 0.050 |
Why?
|
Antineoplastic Agents | 1 | 2008 | 627 | 0.050 |
Why?
|
Intention | 1 | 2022 | 65 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2006 | 1303 | 0.050 |
Why?
|
Physician-Patient Relations | 1 | 2024 | 380 | 0.050 |
Why?
|
Peripheral Vascular Diseases | 1 | 2021 | 46 | 0.050 |
Why?
|
Liver | 1 | 2005 | 754 | 0.050 |
Why?
|
Glucosides | 1 | 2020 | 12 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2024 | 551 | 0.040 |
Why?
|
Interviews as Topic | 2 | 2016 | 471 | 0.040 |
Why?
|
Administrative Claims, Healthcare | 1 | 2019 | 10 | 0.040 |
Why?
|
Tennessee | 1 | 2019 | 16 | 0.040 |
Why?
|
Benzhydryl Compounds | 1 | 2020 | 47 | 0.040 |
Why?
|
Clinical Competence | 1 | 2004 | 640 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2023 | 1208 | 0.040 |
Why?
|
Clinical Coding | 1 | 2019 | 42 | 0.040 |
Why?
|
United Nations | 2 | 2009 | 4 | 0.040 |
Why?
|
Government | 1 | 2018 | 8 | 0.040 |
Why?
|
Bombs | 1 | 2018 | 3 | 0.040 |
Why?
|
Syria | 1 | 2018 | 12 | 0.040 |
Why?
|
Epidemiological Monitoring | 1 | 2018 | 25 | 0.040 |
Why?
|
Propensity Score | 1 | 2018 | 130 | 0.040 |
Why?
|
Mass Casualty Incidents | 1 | 2018 | 30 | 0.040 |
Why?
|
Surveys and Questionnaires | 2 | 2018 | 2553 | 0.040 |
Why?
|
Health Resources | 1 | 2018 | 80 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 965 | 0.040 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2015 | 9 | 0.030 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2015 | 16 | 0.030 |
Why?
|
Quetiapine Fumarate | 1 | 2015 | 13 | 0.030 |
Why?
|
Selection Bias | 1 | 2015 | 27 | 0.030 |
Why?
|
Neuralgia | 1 | 2015 | 20 | 0.030 |
Why?
|
Amines | 1 | 2015 | 30 | 0.030 |
Why?
|
Heparin | 2 | 2008 | 112 | 0.030 |
Why?
|
Disease Progression | 1 | 2019 | 935 | 0.030 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2015 | 78 | 0.030 |
Why?
|
Analgesics | 1 | 2015 | 98 | 0.030 |
Why?
|
Triage | 1 | 2015 | 110 | 0.030 |
Why?
|
Community-Acquired Infections | 1 | 2014 | 86 | 0.030 |
Why?
|
Placebos | 1 | 2013 | 74 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 2016 | 270 | 0.030 |
Why?
|
Enoxaparin | 1 | 2013 | 17 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2015 | 668 | 0.030 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2013 | 29 | 0.030 |
Why?
|
Emotions | 1 | 2016 | 221 | 0.030 |
Why?
|
Nasal Sprays | 1 | 2012 | 2 | 0.030 |
Why?
|
Nebulizers and Vaporizers | 1 | 2012 | 28 | 0.030 |
Why?
|
Bipolar Disorder | 1 | 2015 | 252 | 0.030 |
Why?
|
Computer Graphics | 1 | 2012 | 23 | 0.030 |
Why?
|
Critical Care | 1 | 2015 | 400 | 0.020 |
Why?
|
International Normalized Ratio | 1 | 2011 | 35 | 0.020 |
Why?
|
North Carolina | 1 | 2011 | 62 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2012 | 135 | 0.020 |
Why?
|
Pulmonary Embolism | 1 | 2013 | 184 | 0.020 |
Why?
|
Computer-Assisted Instruction | 1 | 2011 | 75 | 0.020 |
Why?
|
Patient Preference | 1 | 2011 | 75 | 0.020 |
Why?
|
Health Literacy | 1 | 2011 | 77 | 0.020 |
Why?
|
Voluntary Health Agencies | 1 | 2009 | 4 | 0.020 |
Why?
|
Rape | 1 | 2009 | 15 | 0.020 |
Why?
|
Body Weight | 1 | 2011 | 396 | 0.020 |
Why?
|
Sodium Chloride | 1 | 2008 | 58 | 0.020 |
Why?
|
Age Distribution | 1 | 2009 | 269 | 0.020 |
Why?
|
Lipids | 1 | 2011 | 304 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2009 | 186 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2008 | 174 | 0.020 |
Why?
|
Bhutan | 1 | 2008 | 20 | 0.020 |
Why?
|
Elephantiasis, Filarial | 1 | 2007 | 9 | 0.020 |
Why?
|
Myanmar | 1 | 2007 | 10 | 0.020 |
Why?
|
Yellow Fever | 1 | 2007 | 3 | 0.020 |
Why?
|
Colombia | 1 | 2007 | 14 | 0.020 |
Why?
|
Animals | 1 | 2006 | 19324 | 0.020 |
Why?
|
Leishmaniasis, Cutaneous | 1 | 2007 | 12 | 0.020 |
Why?
|
Half-Life | 1 | 2007 | 67 | 0.020 |
Why?
|
Chagas Disease | 1 | 2007 | 34 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2008 | 53 | 0.020 |
Why?
|
Hunger | 1 | 2006 | 17 | 0.020 |
Why?
|
Time | 1 | 2006 | 27 | 0.020 |
Why?
|
Social Welfare | 1 | 2006 | 22 | 0.020 |
Why?
|
Leukocyte Common Antigens | 1 | 2006 | 53 | 0.020 |
Why?
|
North America | 1 | 2006 | 115 | 0.020 |
Why?
|
Coercion | 1 | 2006 | 54 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2006 | 109 | 0.020 |
Why?
|
Lymphoma, B-Cell | 1 | 2006 | 58 | 0.020 |
Why?
|
Multiple Organ Failure | 1 | 2006 | 41 | 0.020 |
Why?
|
Clinical Trials Data Monitoring Committees | 1 | 2006 | 5 | 0.020 |
Why?
|
Cambodia | 1 | 2005 | 18 | 0.020 |
Why?
|
Confidentiality | 1 | 2006 | 53 | 0.020 |
Why?
|
Self-Help Groups | 1 | 2005 | 38 | 0.020 |
Why?
|
Attitude | 1 | 2006 | 100 | 0.020 |
Why?
|
Prisons | 1 | 2006 | 113 | 0.020 |
Why?
|
Quinine | 1 | 2005 | 3 | 0.020 |
Why?
|
Chloroquine | 1 | 2005 | 48 | 0.020 |
Why?
|
Doxycycline | 1 | 2005 | 38 | 0.020 |
Why?
|
Informed Consent | 1 | 2006 | 130 | 0.020 |
Why?
|
Drug Resistance, Microbial | 1 | 2005 | 42 | 0.020 |
Why?
|
Antimalarials | 1 | 2005 | 67 | 0.020 |
Why?
|
Erythrocytes | 1 | 2005 | 154 | 0.010 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2008 | 370 | 0.010 |
Why?
|